Most recently the leader of buzzy startup Tessera Therapeutics, Severino will look to improve the fortunes of a company ...

The deal gives Argenx a drug prospect aimed at the protein target CD122, an approach that’s recently gained traction among ...

Shares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with ...

Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s ...

In a victory for Robert F. Kennedy Jr.’s “MAHA” agenda, panelists narrowly recommended broader use of four peptides despite a ...

The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most ...

While the possibility of levies on branded pharmaceuticals have had a limited impact on drugmaker revenues, tariffs of up to ...

The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British ...

A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck ...

The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions ...

The decision to no longer seek approval of amlitelimab is the latest setback for a treatment once hailed as a future ...

The acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from ...